Claim 1: A set of antibodies (ADC) containing the (1) structure,Or salt, where AB includes an anti-PRLR antibody, including: (1) a heavy chain variable region, including a CDR1 sequence, including SEQ ID No.3, a CDR2 sequence, including SEQ ID No.4, and a CDRH3 Qua sequence, including SEQ ID No.4. 5. (2) A region of light chain variables, including CDR1 sequence No. 8 of Chemical Abstracts, CDR2 sequence No. 9 of Chemical Abstracts and CDR3 sequence No. 10 of Chemical Abstracts, and a variation of S239C in a continuous P-chain region. A. ESADA, numbered in accordance with KABAT；(4) N is about 2. Claim 12: A synthetic antibody (ADC) containing (2) formula structure,Or salt, where D includes a pyrethroid (PBD)；AB is an anti-acrylic receptor antibody.This is Val, Z is Ala, Q is 1, 2, 3, 4, 5, 6, 7, or 8. Anti-PRLR antibodies include: (1) a heavy chain variable region, including a CDR1 sequence, including SEQ ID No. 3, a CDR2 sequence, including SEQ ID No. 4, and a purchased CDR3 sequence. (2) A light chain variable region, including CDR1 sequence, including SEQ ID No.8, CDR2 sequence, including SEQ ID No.9 and CDR3 sequence, including SEQ ID No.10； and (3) variation of S239C included in CONS region. A. Heavy chain test, whose number is in accordance with KABAT；(4) N is about 2.Reivindicación 1: Un conjugado de anticuerpo-fármaco (ADC) que comprende la estructura de la fórmula (1), o una sal del mismo, en el que Ab comprende un anticuerpo anti-PRLR que comprende: i) una región variable de cadena pesada que comprende una secuencia de CDRH1 que comprende la SEQ ID Nº 3, una secuencia de CDRH2 que comprende la SEQ ID Nº 4, y una secuencia de CDRH3 qua comprende la SEQ ID Nº 5； ii) una región variable de cadena ligera que comprende una secuencia de CDRL1 que comprende la SEQ ID Nº 8, una secuencia de CDRL2 que comprende la SEQ ID Nº 9, y una secuencia de CDRL3 que comprende la SEQ ID Nº 10； iii) una mutación que comprende S239C en una región constante de cadena pesada, en l
